Immix Biopharma (NASDAQ:IMMX) Stock Price Target Raised at Morgan Stanley

Immix Biopharma (NASDAQ:IMMX – Get Free Report) had its price target hoisted by analysts at Morgan Stanley from $20.00 to $21.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would suggest a potential upside of 193.26% from the company’s previous close.

IMMX has been the topic of a number of other research reports. HC Wainwright upped their target price on Immix Biopharma from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Needham & Company LLC upped their price objective on Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Finally, Mizuho cut their target price on shares of Immix Biopharma from $23.00 to $22.00 and set an “outperform” rating for the company in a report on Wednesday. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immix Biopharma currently has an average rating of “Moderate Buy” and an average price target of $24.14.

View Our Latest Stock Analysis on IMMX

Immix Biopharma Price Performance

NASDAQ:IMMX traded down $0.04 during mid-day trading on Wednesday, hitting $7.16. The company’s stock had a trading volume of 138,752 shares, compared to its average volume of 1,307,416. Immix Biopharma has a 1 year low of $3.78 and a 1 year high of $15.10. The stock has a market cap of $600.16 million, a price-to-earnings ratio of -8.58 and a beta of 0.29. The business’s fifty day moving average is $9.57 and its two-hundred day moving average is $9.60.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Analysts anticipate that Immix Biopharma will post -0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

A number of institutional investors have recently modified their holdings of IMMX. Aquatic Capital Management LLC purchased a new stake in shares of Immix Biopharma in the third quarter valued at approximately $771,000. Mathes Company Inc. raised its stake in shares of Immix Biopharma by 23.5% during the 3rd quarter. Mathes Company Inc. now owns 13,150 shares of the company’s stock worth $137,000 after buying an additional 2,500 shares during the period. Marshall Wace LLP lifted its position in shares of Immix Biopharma by 3.3% during the 3rd quarter. Marshall Wace LLP now owns 1,854,215 shares of the company’s stock valued at $19,284,000 after buying an additional 59,307 shares in the last quarter. Blue Owl Capital Holdings LP lifted its position in shares of Immix Biopharma by 37.6% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 602,047 shares of the company’s stock valued at $6,264,000 after buying an additional 164,495 shares in the last quarter. Finally, Voya Investment Management LLC purchased a new position in shares of Immix Biopharma during the 3rd quarter valued at approximately $116,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Immix Biopharma

Here are a few of the latest headlines about IMMX:

  • Positive Sentiment: Mizuho continues to rate the stock Outperform. Its revised $22 target still implies significant upside from the recent price, although it is lower than its prior $23 target. Mizuho stock recommendations
  • Negative Sentiment: HC Wainwright cut its FY2027 loss estimate to $0.86 per share from $0.20, and lowered Q3 and Q4 2027 estimates to losses of $0.22 and $0.24 per share. These revisions signal expectations for deeper losses than previously forecast.
  • Negative Sentiment: Mizuho’s price-target reduction from $23 to $22 is a modest negative, despite the continued Outperform rating.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Further Reading

Analyst Recommendations for Immix Biopharma (NASDAQ:IMMX)

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.